Analyst Ratings for [ICPT] Intercept Pharmaceuticals, Inc.

7/13/23	Upgrades	Sell Buy	X
ICPT Intercept Pharma H.C. Wainwright
$8 $19
6/29/23	Upgrades	Hold Buy	X
ICPT Intercept Pharma Canaccord Genuity
$12 $18
5/23/23	Downgrades	Buy Hold	X
ICPT Intercept Pharma Needham
5/22/23	Downgrades	Neutral Sell	X
ICPT Intercept Pharma H.C. Wainwright
$8
5/17/23	Downgrades	Outperform Mkt Perform	X
ICPT Intercept Pharma Raymond James
1/11/22	Upgrades	Neutral Buy	X
ICPT Intercept Pharma B. Riley Securities
$25 $30
5/25/21	Downgrades	Buy Neutral	X
ICPT Intercept Pharma B. Riley Securities
$18
3/12/21	Upgrades	Sell Neutral	X
ICPT Intercept Pharma H.C. Wainwright
$21
2/23/21	Downgrades	Neutral Sell	X
ICPT Intercept Pharma H.C. Wainwright
$25
1/15/21	Downgrades	Neutral Underperform	X
ICPT Intercept Pharma BofA Securities
$40 $27
6/25/19	Initiated	Hold	X
ICPT Intercept Pharma Stifel
$89
5/10/19	Reiterated	Buy	X
ICPT Intercept Pharma B. Riley FBR
$169 $158
5/3/19	Upgrades	Mkt Perform Outperform	X
ICPT Intercept Pharma Wells Fargo
3/1/19	Upgrades	Sec Perform Outperform	X
ICPT Intercept Pharma RBC Capital Mkts
$130
2/22/19	Downgrades	Mkt Perform Underperform	X
ICPT Intercept Pharma SVB Leerink
$70
2/15/19	Reiterated	Underperform	X
ICPT Intercept Pharma BofA/Merrill
$68 $79
2/4/19	Upgrades	Outperform Strong Buy	X
ICPT Intercept Pharma Raymond James
$184
1/31/19	Initiated	Outperform	X
ICPT Intercept Pharma Credit Suisse
$167
1/30/19	Upgrades	Mkt Perform Mkt Outperform	X
ICPT Intercept Pharma JMP Securities
1/23/19	Initiated	Buy	X
ICPT Intercept Pharma UBS
$130
1/14/19	Upgrades	Hold Buy	X
ICPT Intercept Pharma Laidlaw
$130
12/12/18	Initiated	Buy	X
ICPT Intercept Pharma B. Riley FBR
$155
11/19/18	Upgrades	Perform Outperform	X
ICPT Intercept Pharma Oppenheimer
10/2/18	Downgrades	Strong Buy Outperform	X
ICPT Intercept Pharma Raymond James
10/1/18	Resumed	Overweight	X
ICPT Intercept Pharma Cantor Fitzgerald
$170
9/12/18	Initiated	Buy	X
ICPT Intercept Pharma ROTH Capital
$192
8/15/18	Downgrades	Outperform Sec Perform	X
ICPT Intercept Pharma RBC Capital Mkts
8/6/18	Upgrades	Sell Buy	X
ICPT Intercept Pharma Goldman
8/3/18	Downgrades	Buy Hold	X
ICPT Intercept Pharma Laidlaw
$90 $95
6/28/18	Initiated	Strong Buy	X
ICPT Intercept Pharma Raymond James
2/7/18	Downgrades	Neutral Sell	X
ICPT Intercept Pharma Goldman

ICPT Intercept Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.